Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8537688 | Pulmonary Pharmacology & Therapeutics | 2018 | 37 Pages |
Abstract
The clinical study demonstrated that in subjects with poor inhalation technique the use of the AeroChamber Plus® Flow-Vu® spacer increased the bioavailability of Symbicort® pMDI to a level observed in subjects with good inhalation technique without a spacer. The findings from the in vitro study support the fine particle dose characteristics of Symbicort® pMDI with the AeroChamber Plus® Flow-Vu® spacer.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Michael Gillen, Pablo Forte, Jan Olof Svensson, Rosa Lamarca, Joanna Burke, Karolina Rask, Ulrika Larsdotter Nilsson, Göran Eckerwall,